Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: A model for treatment

Erika Martinelli, Teresa Troiani, Floriana Morgillo, Maria Carmela Piccirillo, Katia Monaco, Maria Pia Morelli, Tina Cascone, Fortunato Ciardiello

Research output: Contribution to journalArticle

Abstract

The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to relevant processes in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis and metastatic spread. EGFR-blocking monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors have been developed as anticancer drugs. Although anti-EGFR agents are active in a subset of cancer patients, constitutive resistance in a large number of patients and the development of acquired resistance in initially responding patients are a relevant clinical issue. A major problem is that intrinsic and/or acquired resistance can occur, and it could be due to the activation of alternative cancer cell growth controlling pathways. One mechanism linked to acquired resistance to EGFR-inhibitor treatment, in particular, is the activation of uncontrolled, tumor-induced angiogenesis through an increase in vascular endothelial growth factor (VEGF) secretion by cancer cells. Significant and sustained antitumor activity in this context can be obtained by combining selective anti-EGFR drugs with antiangiogenic agents. In this review, we focus on the preclinical and clinical evidence showing that an approach combining anti-EGFR and antiangiogenic drugs is feasible and could represent a paradigm for a rational combined multi-targeted treatment of cancer.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalTargeted Oncology
Volume1
Issue number3
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Neoplasms
Therapeutics
Blocking Antibodies
Angiogenesis Inhibitors
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Cell Death
Monoclonal Antibodies
Cell Proliferation
Growth

Keywords

  • Bevacizumab
  • Cetuximab
  • Epidermal growth factor receptor
  • Erlotinib
  • Molecular targeted therapy
  • Vascular endothelial growth factor receptor
  • ZD6474

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs : A model for treatment. / Martinelli, Erika; Troiani, Teresa; Morgillo, Floriana; Piccirillo, Maria Carmela; Monaco, Katia; Morelli, Maria Pia; Cascone, Tina; Ciardiello, Fortunato.

In: Targeted Oncology, Vol. 1, No. 3, 07.2006, p. 123-129.

Research output: Contribution to journalArticle

Martinelli, E, Troiani, T, Morgillo, F, Piccirillo, MC, Monaco, K, Morelli, MP, Cascone, T & Ciardiello, F 2006, 'Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: A model for treatment', Targeted Oncology, vol. 1, no. 3, pp. 123-129. https://doi.org/10.1007/s11523-006-0022-5
Martinelli, Erika ; Troiani, Teresa ; Morgillo, Floriana ; Piccirillo, Maria Carmela ; Monaco, Katia ; Morelli, Maria Pia ; Cascone, Tina ; Ciardiello, Fortunato. / Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs : A model for treatment. In: Targeted Oncology. 2006 ; Vol. 1, No. 3. pp. 123-129.
@article{d7fce5f79cd14ef5ba46b94381b721f5,
title = "Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: A model for treatment",
abstract = "The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to relevant processes in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis and metastatic spread. EGFR-blocking monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors have been developed as anticancer drugs. Although anti-EGFR agents are active in a subset of cancer patients, constitutive resistance in a large number of patients and the development of acquired resistance in initially responding patients are a relevant clinical issue. A major problem is that intrinsic and/or acquired resistance can occur, and it could be due to the activation of alternative cancer cell growth controlling pathways. One mechanism linked to acquired resistance to EGFR-inhibitor treatment, in particular, is the activation of uncontrolled, tumor-induced angiogenesis through an increase in vascular endothelial growth factor (VEGF) secretion by cancer cells. Significant and sustained antitumor activity in this context can be obtained by combining selective anti-EGFR drugs with antiangiogenic agents. In this review, we focus on the preclinical and clinical evidence showing that an approach combining anti-EGFR and antiangiogenic drugs is feasible and could represent a paradigm for a rational combined multi-targeted treatment of cancer.",
keywords = "Bevacizumab, Cetuximab, Epidermal growth factor receptor, Erlotinib, Molecular targeted therapy, Vascular endothelial growth factor receptor, ZD6474",
author = "Erika Martinelli and Teresa Troiani and Floriana Morgillo and Piccirillo, {Maria Carmela} and Katia Monaco and Morelli, {Maria Pia} and Tina Cascone and Fortunato Ciardiello",
year = "2006",
month = "7",
doi = "10.1007/s11523-006-0022-5",
language = "English",
volume = "1",
pages = "123--129",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs

T2 - A model for treatment

AU - Martinelli, Erika

AU - Troiani, Teresa

AU - Morgillo, Floriana

AU - Piccirillo, Maria Carmela

AU - Monaco, Katia

AU - Morelli, Maria Pia

AU - Cascone, Tina

AU - Ciardiello, Fortunato

PY - 2006/7

Y1 - 2006/7

N2 - The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to relevant processes in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis and metastatic spread. EGFR-blocking monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors have been developed as anticancer drugs. Although anti-EGFR agents are active in a subset of cancer patients, constitutive resistance in a large number of patients and the development of acquired resistance in initially responding patients are a relevant clinical issue. A major problem is that intrinsic and/or acquired resistance can occur, and it could be due to the activation of alternative cancer cell growth controlling pathways. One mechanism linked to acquired resistance to EGFR-inhibitor treatment, in particular, is the activation of uncontrolled, tumor-induced angiogenesis through an increase in vascular endothelial growth factor (VEGF) secretion by cancer cells. Significant and sustained antitumor activity in this context can be obtained by combining selective anti-EGFR drugs with antiangiogenic agents. In this review, we focus on the preclinical and clinical evidence showing that an approach combining anti-EGFR and antiangiogenic drugs is feasible and could represent a paradigm for a rational combined multi-targeted treatment of cancer.

AB - The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to relevant processes in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis and metastatic spread. EGFR-blocking monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors have been developed as anticancer drugs. Although anti-EGFR agents are active in a subset of cancer patients, constitutive resistance in a large number of patients and the development of acquired resistance in initially responding patients are a relevant clinical issue. A major problem is that intrinsic and/or acquired resistance can occur, and it could be due to the activation of alternative cancer cell growth controlling pathways. One mechanism linked to acquired resistance to EGFR-inhibitor treatment, in particular, is the activation of uncontrolled, tumor-induced angiogenesis through an increase in vascular endothelial growth factor (VEGF) secretion by cancer cells. Significant and sustained antitumor activity in this context can be obtained by combining selective anti-EGFR drugs with antiangiogenic agents. In this review, we focus on the preclinical and clinical evidence showing that an approach combining anti-EGFR and antiangiogenic drugs is feasible and could represent a paradigm for a rational combined multi-targeted treatment of cancer.

KW - Bevacizumab

KW - Cetuximab

KW - Epidermal growth factor receptor

KW - Erlotinib

KW - Molecular targeted therapy

KW - Vascular endothelial growth factor receptor

KW - ZD6474

UR - http://www.scopus.com/inward/record.url?scp=33749867319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749867319&partnerID=8YFLogxK

U2 - 10.1007/s11523-006-0022-5

DO - 10.1007/s11523-006-0022-5

M3 - Article

AN - SCOPUS:33749867319

VL - 1

SP - 123

EP - 129

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -